| P50 | author | Piergiorgio Messa | Q87983056 |
| | Francesco Locatelli | Q92104990 |
| | Ciro Esposito | Q92911592 |
| | Mario Cozzolino | Q39187915 |
| | Giuseppe Vezzoli | Q44904873 |
| P2093 | author name string | Antonio Bellasi | |
| | Marzia Pasquali | |
| | Patrizia Ondei | |
| | Fabio Malberti | |
| | Giovanni Cancarini | |
| | Giuseppe Pontoriero | |
| | Carlo Maria Guastoni | |
| | Ugo Teatini | |
| P2860 | cites work | Oral phosphate binders in patients with kidney failure | Q28279104 |
| | Presence of valvular calcification predicts the response to cinacalcet: data from the ADVANCE study | Q30682951 |
| | Phosphate binders in chronic kidney disease: a systematic review of recent data | Q31039292 |
| | The DOPPS Practice Monitor for US Dialysis Care: PTH Levels and Management of Mineral and Bone Disorder in US Hemodialysis Patients | Q33702417 |
| | Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients | Q33873467 |
| | Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism | Q34362759 |
| | Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis | Q34828563 |
| | Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study | Q34828835 |
| | Renal osteodystrophy and secondary hyperparathyroidism | Q34973993 |
| | KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). | Q34994912 |
| | Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial | Q35115090 |
| | The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial | Q35576108 |
| | The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial | Q35576155 |
| | Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial | Q35658608 |
| | Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism | Q35682152 |
| | The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism | Q36666922 |
| | Correlates of parathyroid hormone concentration in hemodialysis patients | Q36936601 |
| | Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results | Q36947391 |
| | Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis | Q37595124 |
| | Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism? | Q37891153 |
| | Phosphate binders in moderate chronic kidney disease: where do we stand? | Q38094673 |
| | Nutritional treatment of advanced CKD: twenty consensus statements | Q88802694 |
| | Multicenter study on parathyroidectomy (PTX) in Italy: preliminary results | Q91192255 |
| | NF-κB activation contributes to parathyroid cell proliferation in chronic kidney disease | Q91255780 |
| | One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism | Q92287549 |
| | A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients | Q95357301 |
| | [CKD-MBD, cardiovascular involvement and prognosis] | Q95359404 |
| | What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials? | Q38150052 |
| | What can we learn from a statistically inconclusive trial? Consensus conference on the EVOLVE study results | Q38176813 |
| | Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool. | Q38253227 |
| | Emerging drugs for secondary hyperparathyroidism. | Q38363615 |
| | Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. | Q38382239 |
| | Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. | Q38382242 |
| | Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial | Q38410120 |
| | Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. | Q38436799 |
| | Calcifediol to Treat Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease. | Q38605841 |
| | Etelcalcetide: First Global Approval | Q39024226 |
| | Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis | Q39034625 |
| | Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. | Q39255870 |
| | Vitamin D metabolism and potential effects of vitamin D receptor modulation in chronic kidney disease. | Q39275892 |
| | Uremic Toxicity and Bone in CKD. | Q39345412 |
| | Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide | Q39374348 |
| | Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters | Q39395889 |
| | Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients? | Q39440902 |
| | Cinacalcet: the chemical parathyroidectomy? | Q39719456 |
| | Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic | Q40996542 |
| | Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism | Q42683242 |
| | Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial. | Q43692218 |
| | Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel d-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide). | Q43743367 |
| | COSMOS: the dialysis scenario of CKD-MBD in Europe. | Q43939289 |
| | Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis | Q44835152 |
| | Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis | Q44871721 |
| | The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial | Q45073262 |
| | Dosing of Etelcalcetide vs Cinacalcet for Secondary Hyperparathyroidism-Reply | Q46635515 |
| | Assessment of intradialysis calcium mass balance by a single pool variable-volume calcium kinetic model | Q47983812 |
| | Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing | Q49332215 |
| | CKD-MBD management: what is the role of parathyroidectomy? Results from a nationwide survey in Italy | Q56355649 |
| | The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis | Q62561630 |
| | Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study | Q64120799 |
| | Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS) | Q80867378 |
| | Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients | Q82632904 |
| | A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients | Q86952639 |
| | Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study | Q87969148 |
| P433 | issue | 2 | |
| P921 | main subject | secondary hyperparathyroidism | Q3622611 |
| | position paper | Q7233193 |
| P304 | page(s) | 211-221 | |
| P577 | publication date | 2019-12-18 | |
| P1433 | published in | Journal of Nephrology | Q15765408 |
| P1476 | title | New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology | |
| P478 | volume | 33 | |